Trial Profile
A randomized, double blind, placebo-controlled, multicenter, phase III study comparing the activity of paclitaxel plus trastuzumab plus lapatinib to paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline Research & Development; GSK; Novartis
- 03 Dec 2020 Status changed from completed to discontinued.
- 03 Dec 2019 Status changed from active, no longer recruiting to completed.
- 08 Nov 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.